Donald Trump Administration

This week’s mainstream coverage focused on two administration moves: the Justice Department formally reclassified FDA‑approved marijuana products and state‑licensed medical cannabis from Schedule I to Schedule III in an April 23 order (creating an expedited DEA registration path, easing banking and tax treatment for some firms, and loosening research barriers), and revelations about the White House’s $1 million “Gold Card” investor‑visa program after Commerce Secretary Howard Lutnick told Congress it has produced only one approved applicant despite earlier sales and revenue claims. Reporting tracked the policy’s regulatory history and the immediate political and industry reactions, while scrutiny of the visa program shifted to discrepancies in public claims, fee structures, vetting and legal challenges.

What mainstream outlets often left out were concrete numbers and context that change how the actions look: independent data showing the U.S. medical cannabis market was about $7.6 billion in 2025 and more than 3.6 million registered patients, plus the Section 280E tax rule that left state‑legal sellers facing effective federal rates as high as ~80% — facts that help explain the industry impact of rescheduling. Opinion and analysis pieces (and some independent commentary) emphasized perspectives undercovered by straight reporting: that rescheduling functions as a de facto industry relief/subsidy with symbolic effects on social acceptance and youth risk, that the move may not deliver broad equity or public‑health protections, and that a possible federal intervention in private firms (e.g., Spirit Airlines) signals a readiness to use government power in market stabilization. Readers relying only on mainstream stories would benefit from more detail on the DEA/DOJ rulemaking record (public comments, legal rationale), empirical studies on cannabis health impacts (especially adolescent brain development), transparent disclosure about vetting and revenue claims for the Gold Card rollout, and sustained reporting on distributional consequences raised by contrarian voices.